Orthometrix, Inc. (OMRX) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 0.01 means the share price is 0.01 times one year of earnings per share.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerOrthometrix, Inc. (OMRX) trades at $0.0001. Orthometrix, Inc. specializes in developing and marketing technologies aimed at improving musculoskeletal mobility and treating related pain. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for OMRX: OMRX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Orthometrix, Inc. (OMRX) Healthcare & Pipeline Overview
Orthometrix, Inc. focuses on musculoskeletal health, providing diagnostic and therapeutic solutions across healthcare, veterinary, and sports sectors. Its patented technologies in bone measurement, rehabilitation, and pain management position it within the niche medical specialties market, serving diverse customer segments globally.
What Is the Investment Thesis for OMRX?
Orthometrix, Inc. presents a focused investment opportunity within the medical specialties sector, driven by its proprietary technologies in musculoskeletal diagnostics and therapeutics. The company's gross margin of 69.6% indicates strong pricing power and efficient cost management. A key value driver is the increasing demand for non-invasive pain management solutions and rehabilitation technologies, particularly for conditions like osteoarthritis and plantar fasciitis. Growth catalysts include expanding the market reach of its ESWT systems and leveraging its patented vibration technology in new applications. However, the company's small market capitalization and OTC listing introduce liquidity and regulatory risks. The high beta of -51.49 suggests extreme volatility relative to the market. While the profit margin of 27.2% is attractive, investors should carefully assess the sustainability of these earnings given the competitive landscape and the company's limited resources.
Based on FMP financials and quantitative analysis
OMRX Key Highlights
Gross margin of 69.6% indicates strong profitability in its product offerings.
- Profit margin of 27.2% demonstrates efficient cost management and revenue generation.
- Beta of -51.49 suggests the stock price moves inversely and with greater volatility compared to the overall market.
- The company serves diverse markets including healthcare, veterinary, and sports/fitness, providing multiple revenue streams.
- Specializes in non-invasive technologies to treat musculoskeletal conditions, aligning with the growing demand for less invasive treatments.
Who Are OMRX's Competitors?
OMRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BJDX Bluejay Diagnostics, Inc. | $0.84 | -1.12% | 30 5-pillar | |
| NVNO enVVeno Medical Corporation | $8.10 | +0.75% | $5.63M | 33 5-pillar |
| BDMD Baird Medical Investment Holdings Limited | $0.75 | +0.91% | $31.7M | — |
| SNWV SANUWAVE Health, Inc. | $4.82 | +4.33% | $41.5M | 36 5-pillar |
| SRTS Sensus Healthcare, Inc. | $2.98 | +1.02% | $49.1M | 31 5-pillar |
| HYPD Hyperion DeFi, Inc. | $3.73 | +1.91% | $56.5M | 36 5-pillar |
| LNSR LENSAR, Inc. | $6.75 | +2.74% | $82.9M | 45 5-pillar |
| APYX Apyx Medical Corporation | $2.55 | +2.00% | $107M | 33 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OMRX's Key Strengths?
Proprietary technologies in bone and muscle measurement.
- Diverse customer base across healthcare, veterinary, and sports markets.
- High gross profit margin.
- Established presence in the musculoskeletal health market.
What Are OMRX's Weaknesses?
Small market capitalization and limited financial resources.
- OTC listing increases liquidity and regulatory risks.
- High beta indicates significant stock price volatility.
- Limited brand recognition compared to larger competitors.
What Are the Key Risks for OMRX?
Negative return on equity (-15.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from larger medical device companies with greater resources.
- Regulatory changes affecting the approval and reimbursement of medical devices.
- Technological obsolescence of existing products.
- Limited liquidity due to OTC listing and low trading volume.
- Dependence on key personnel and limited management depth.
What Are OMRX's Competitive Advantages?
- Patented Technologies: Orthometrix holds patents for its motorized exercise systems and vibration technology, providing a competitive advantage.
- Specialized Expertise: The company has deep expertise in musculoskeletal diagnostics and therapeutics, built over several decades.
- Established Customer Base: Orthometrix has a loyal customer base in the healthcare, veterinary, and sports/fitness markets.
- Integrated Product Portfolio: The company offers a comprehensive range of products and services for bone and muscle health.
What Does OMRX Do?
Founded in 1993 and headquartered in Naples, Florida, Orthometrix, Inc., formerly known as Norland Medical Systems, Inc., has evolved into a developer and marketer of technologies designed to enhance musculoskeletal mobility and alleviate associated pain. The company's portfolio includes peripheral quantitative computed tomography (pQCT) bone and muscle measurement systems used in research and clinical settings. These systems provide detailed assessments of bone density and muscle mass, aiding in the diagnosis and monitoring of conditions like osteoporosis and sarcopenia. Orthometrix also offers patented motorized exercise systems incorporating vibration technology, targeting rehabilitation, physical therapy, and sports medicine applications. These systems are designed to improve muscle strength, flexibility, and overall physical performance. Additionally, the company provides human performance measurement systems for tracking progress in power and mobility, as well as extracorporeal shock wave therapy (ESWT) systems for non-invasive pain management, particularly for plantar fasciitis. Orthometrix serves a diverse clientele, including healthcare providers, veterinary clinics, sports teams, fitness centers, and individual consumers. The company markets its products and services both domestically and internationally, focusing on delivering innovative solutions for musculoskeletal health and pain management.
What Products and Services Does OMRX Offer?
- Develops peripheral quantitative computed tomography (pQCT) bone and muscle measurement systems.
- Markets and services pQCT systems for research and clinical applications.
- Offers patented motorized exercise systems for rehabilitation, physical therapy, and sports medicine.
- Provides human performance measurement systems for monitoring improvement in power and mobility.
- Markets and services extracorporeal shock wave therapy (ESWT) systems for pain management.
- Sells patented motorized exercise systems to professional teams, fitness centers, and the general public.
How Does OMRX Make Money?
- Sales of diagnostic and therapeutic medical devices to healthcare providers and research institutions.
- Service and maintenance contracts for its installed base of medical equipment.
- Direct sales of rehabilitation and fitness equipment to consumers.
- Partnerships with sports teams and fitness centers for product distribution and marketing.
What Industry Does OMRX Operate In?
Orthometrix, Inc. operates within the medical specialties industry, which is characterized by rapid technological advancements and increasing demand for minimally invasive procedures. The market for musculoskeletal diagnostic and therapeutic devices is driven by an aging population, rising obesity rates, and growing awareness of sports-related injuries. Competitors include companies like ACBM (AccuBioTech Medical), ARYX (ARYx Therapeutics), AXMP (Advanced Medical Payment), HDVY (Hardevy), and IBXG (IBio), each with varying focuses within the broader medical device landscape. Orthometrix differentiates itself through its patented vibration technology and integrated approach to bone and muscle health.
Who Are OMRX's Key Customers?
- Hospitals and clinics using bone and muscle measurement systems for diagnostics.
- Research institutions conducting studies on bone and muscle health.
- Physical therapy centers and rehabilitation clinics using motorized exercise systems.
- Sports teams and athletes using performance measurement and rehabilitation equipment.
- Individual consumers purchasing home-use fitness and rehabilitation products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Orthometrix, Inc. operates in the Healthcare sector. It is headquartered in Naples, United States.
Key Financial Metrics
Return on equity for Orthometrix, Inc. stands at -15.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 51.4%, showing how much profit it generates from its asset base. OMRX trades at a trailing price-to-earnings ratio of 0.01, below the Healthcare sector average of ~21.10x. A current ratio of 5.35 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Orthometrix, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
OMRX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
OMRX Latest News
No recent news available for OMRX.
OMRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for OMRX.
Price Targets
Wall Street price target analysis for OMRX.
OMRX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for OMRX; grades run from A+ (80-100) to F (below 30).
Leadership: Reynald G. Bonmati
Managing Director
Reynald G. Bonmati serves as the Managing Director of Orthometrix, Inc., overseeing the company's operations and strategic direction. His background includes experience in managing small teams and guiding the company's focus on musculoskeletal mobility technologies. Bonmati is responsible for the overall performance of Orthometrix, including product development, marketing, and sales. He manages a team of 7 employees.
Track Record: Under Bonmati's leadership, Orthometrix has continued to develop and market its core product lines, including bone and muscle measurement systems and rehabilitation technologies. He has focused on serving healthcare, veterinary, and sports/fitness markets. Specific milestones and achievements during his tenure are not detailed in the provided data.
OMRX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Orthometrix, Inc. may not meet minimum financial standards or reporting requirements to be listed on higher tiers like OTCQX or OTCQB, or major exchanges like NYSE or NASDAQ. Companies in this tier often have limited operating history, minimal assets, or are undergoing financial distress. Investing in companies on the OTC Other tier carries significantly higher risks compared to those listed on regulated exchanges due to the lack of stringent listing requirements and regulatory oversight.
- OTC Tier: OTC Other
- Limited liquidity due to low trading volume.
- Lack of regulatory oversight and financial reporting requirements.
- Higher potential for fraud and manipulation.
- Greater price volatility compared to exchange-listed stocks.
- Limited access to company information and management.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Determine the company's revenue sources and customer base.
- Understand the company's capital structure and debt obligations.
- Consult with a financial advisor before investing.
- The company has been in operation since 1993.
- Orthometrix possesses patented technologies.
- The company serves diverse markets including healthcare, veterinary, and sports/fitness.
- Orthometrix has a functional website and contact information.
OMRX Healthcare Stock FAQ
What do analysts say about OMRX stock?
Given its OTC listing and small market capitalization, Orthometrix, Inc. may not be widely covered by analysts. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. The company's gross and profit margins are positive, but the high beta suggests significant volatility.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.